Summary

According to the recently published report ’Metabotropic Glutamate Receptor 7 - Drugs In Development, 2022’; Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) pipeline Target constitutes close to 7 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes.

Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) - Metabotropic glutamate receptor 7 is a protein encoded by the GRM7 gene. G-protein coupled receptor for glutamate. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase.

The report ’Metabotropic Glutamate Receptor 7 - Drugs In Development, 2022’ outlays comprehensive information on the Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II and Preclinical stages are 2 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Undisclosed and Women’s Health which include indications Anxiety Disorders, Post-Traumatic Stress Disorder (PTSD), Alzheimer’s Disease, Attention Deficit Hyperactivity Disorder (ADHD), Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy), Drug-Induced Dyskinesia, Infantile Spasm (West Syndrome), Lennox-Gastaut Syndrome, Opium (Opioid) Addiction, Parkinson’s Disease, Post Partum Depression (Maternal Depression / Postnatal Depression), Rett Syndrome, Status Epilepticus, Unspecified and Visceral Pain.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope

  • The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7)
  • The report reviews Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) targeted therapeutics




Reasons To Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope